A new survey from the American
Association of Diabetes Educators (AADE) found that Medicare’s
Competitive Bidding Program (CBP) significantly reduced beneficiary
choice and access to commonly used diabetes testing supplies. The
lack of choice forces beneficiaries to switch to unfamiliar or
unsuitable testing systems, and can have dire health consequences.
AADE’s survey is the latest in a
continuous round of reports by AADE and others pointing out the
inherent problems with the CBP. Last year, a National Minority
Quality Forum report showed a direct link to increases in mortality
and complications, inpatient admission and supplier costs. The
unintended consequences from switching testing supplies results in
diminished or ceasing altogether of blood sugar testing, leading to
an increased risk for complications such as blindness, kidney damage,
cardiovascular disease and lower-limb amputations.
The new survey reinforces AADE secret
shopper surveys done in 2011 and 2013 showing the same downward trend
in availability and access.
“Evidence continues to show that the
competitive bidding process is failing people with diabetes and
putting them at unnecessary risk,” said Kellie Antinori-Lent, a
diabetes clinical nurse specialist at the University of Pittsburgh
Medical Center. “Patient safety and choice must come first.”
Key findings from the survey include:
• The number of manufacturers making
diabetes testing supplies (DTS) available under National Mail Order
(NMO) has fallen 50 percent since the start of the Competitive
Bidding Program (CPB)
• The number of diabetes testing systems available under NMO is less than half the number available in 2009 before the CPB started
• Many suppliers do not offer models covering 50 percent of the market share of the DTS
• Suppliers do not provide consistent information about inventory to customers
• The number of diabetes testing systems available under NMO is less than half the number available in 2009 before the CPB started
• Many suppliers do not offer models covering 50 percent of the market share of the DTS
• Suppliers do not provide consistent information about inventory to customers
The Centers for Medicare and Medicaid
Services (CMS) established the competitive bidding program for
mail-order suppliers of diabetes testing equipment in January 2011.
Soon after, widespread anecdotal reports suggested that the suppliers
were denying access to the specific brands and types of equipment
promised to be available on Medicare.gov. The most recent study
showed some improvements, finding fewer discrepancies between the
information provided on Medicare.gov and what is available to
consumers.
To ensure beneficiary safety and
well-being, a complete review of the program is necessary. AADE
applauds the recent announcement by CMS to delay Round 2019 of the
Competitive Bidding Program in hopes that the process can be
overhauled to reflect evidence based data and best practices.
Beneficiaries should have access to their preferred testing supplies,
directed by their healthcare team.
No comments:
Post a Comment